A detailed history of Summit Trail Advisors, LLC transactions in Incyte Corp stock. As of the latest transaction made, Summit Trail Advisors, LLC holds 10,650 shares of INCY stock, worth $1.11 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
10,650
Previous 7,854 35.6%
Holding current value
$1.11 Million
Previous $534,000 69.1%
% of portfolio
0.01%
Previous 0.01%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

BUY
$67.27 - $86.96 $188,086 - $243,140
2,796 Added 35.6%
10,650 $903,000
Q2 2025

Aug 14, 2025

BUY
$55.17 - $71.22 $433,305 - $559,361
7,854 New
7,854 $534,000
Q4 2024

Jan 29, 2025

SELL
$65.08 - $83.38 $1,171 - $1,500
-18 Reduced 0.33%
5,452 $376,000
Q3 2024

Nov 12, 2024

BUY
$57.33 - $68.61 $313,595 - $375,296
5,470 New
5,470 $361,000
Q1 2018

May 21, 2018

BUY
$83.06 - $100.98 $1.96 Million - $2.38 Million
23,583 Added 3447.81%
24,267 $24,000
Q4 2017

Feb 14, 2018

BUY
$93.56 - $116.6 $63,995 - $79,754
684
684 $65,000

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $23.2B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Summit Trail Advisors, LLC Portfolio

Follow Summit Trail Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Summit Trail Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Summit Trail Advisors, LLC with notifications on news.